Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

0.7836 +0.0336 (+4.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp

< Previous 1 2 3 4 5 Next >
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
 
Via Benzinga
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Lexaria Bioscience' Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension
 
Via Benzinga
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
 
Via Benzinga
Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH
Lexaria Bioscience Corp (NASDAQ: LEXX) announces that its animal study HOR-A22-1 has been completed, showing significant enhancement in the oral delivery of the  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Why Is Nikola (NKLA) Stock Down Today?
Nikola (NKLA) stock is taking a beating on Tuesday after the company announced bad news alongside its latest earnings report. 
Via InvestorPlace
Novavax Layoffs 2023: What to Know About the Latest NVAX Job Cuts
Novavax (NVAX) layoffs are on the way as the vaccine maker revealed plans to cut a large portion of its workforce on Tuesday! 
Via InvestorPlace
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
Lexaria Bioscience (LEXX) stock is falling on Tuesday after the company revealed details about its public share offering. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why ClearOne Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) gained 74.2% to $0.2701 in pre-market trading after gaining around 7% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in 
Via Benzinga
$1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by over 70 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD
 
Via Benzinga
This BioTech Company Using CBD For Enhanced Hypertension Treatment Could Be One To Watch
Lexaria Bioscience Corp. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Lexaria Gets FDA's Positive Feedback On Pre-Clinical Trial Of Hypertension Candidate
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting... 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday. 
Via Benzinga
Why Shares Of Lexaria Biosciences Are Trading Higher
Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology. 
Via Benzinga
Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday. 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria expects to begin dosing this summer as part of a human... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.